METASTATIC NON-SMALL CELL LUNG CANCER

This study tests whether combining the drug tislelizumab with other experimental drugs, with or without chemotherapy, can shrink tumors in people with advanced non-small cell lung cancer who haven't had treatment yet. About 400 adults with either high or low PD-L1 levels will tak…

This study tests whether adding a new drug (APL-101) to standard treatment (osimertinib) can better control advanced EGFR-mutated lung cancer. About 27 adults with metastatic non-small cell lung cancer who have been on osimertinib for 8-12 weeks without progression will receive t…

This study compares a new shot form of the immunotherapy drug pembrolizumab (given under the skin) with the standard IV version, both combined with chemotherapy, as a first treatment for adults with metastatic non-small cell lung cancer. The main goal is to see if the shot delive…

This study tests whether adding two drugs (dupilumab and anakinra) to standard immunotherapy can help shrink or control advanced non-small cell lung cancer that has stopped responding to prior immunotherapy. About 33 adults whose cancer progressed after PD-1/PD-L1 treatment will …

This study tests whether adding a new drug (relatlimab) to standard immunotherapy (nivolumab) and chemotherapy works better than nivolumab plus chemotherapy alone for people with advanced or recurrent non-small cell lung cancer. About 468 participants will receive one of the two …

This study tests two new drug combinations (Tedopi plus docetaxel or Tedopi plus nivolumab) in people with advanced non-small-cell lung cancer whose first treatment stopped working. About 105 participants with a specific genetic marker (HLA-A2+) will receive one of the combos or …

This study tests whether adding ramucirumab to the standard drug erlotinib helps people with a specific type of advanced lung cancer (EGFR mutation-positive) live longer without their cancer growing. About 545 people who have not had treatment yet will receive either the combinat…

This study compares a new shot form of the immunotherapy drug pembrolizumab (given under the skin) with the standard IV version, both combined with chemotherapy, as a first treatment for adults in Japan with metastatic non-small cell lung cancer. The goal is to see if the shot wo…

This study tests whether a new drug called volrustomig, combined with chemotherapy, works better than the standard treatment (pembrolizumab plus chemo) for people with advanced non-small cell lung cancer that has spread. About 1,200 adults whose tumors have low levels of a protei…

This study tests whether a new drug combination (datopotamab deruxtecan plus pembrolizumab) works better than standard chemo plus immunotherapy for people with advanced non-small cell lung cancer who haven't had treatment yet. About 1,170 adults with a specific tumor marker (PD-L…

This trial aimed to test a new treatment for people with metastatic non-small cell lung cancer. It used a patient's own immune cells (TILs) that were edited with CRISPR to remove a gene called CISH, potentially making them better at fighting cancer. The study was withdrawn before…

This study tests whether a blood test taken during treatment can show if immunotherapy (pembrolizumab) is working well enough alone, or if adding chemotherapy is needed. About 40 people with stage IV non-small cell lung cancer will give blood samples at different times. The goal …

This early-stage study tests a drug called furmonertinib in 160 people with advanced lung cancer that has certain gene mutations (EGFR or HER2). The goal is to see if the drug is safe and can shrink tumors. Participants have already tried other treatments without success.